The Food and Drug Administration has issued a public health advisory about the immunosuppressant drug, efalizumab (Raptiva) made by Genentech, Inc. Three deaths, possibly a fourth, are connected to use of the drug, used to treat chronic psoriasis.
Researchers at Genentech Inc. have discovered a new mechanism of nerve-cell death that might play a role in Alzheimer's disease, paving the way for potential new treatments to battle the devastating neurodegenerative illness.
Patients receiving Avastin for colon cancer, were 33 percent more likely to develop blood clots than those who did not receive the drug, researchers announced after reviewing 15 clinical trials involving nearly 8,000 patients with advanced cancer.
Genentech is seeking accelerated FDA approval of its drug Avastin, to fight gliobastoma, the most aggressive form of brain cancer with no cure and limited treatment options.
Researchers have redesigned an experimental breast cancer vaccine that delivers a cancer-fighting gene into cells. In experiments with mice, their own bodies then produced immune system proteins as well as tumor-destroying cells. The mice were able to destroy tumors, even those that are drug resistant.
Genentech is revising the label on its drug Rituxan after a woman who was treated with it died from a rare brain infection known as progressive multifocal leukoencephalopathy (PML), according to the U.S. Food and Drug Administration.
Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery. We are committed to serving the public with honesty and integrity in these efforts.
On the Road
Major Medical
Protecting Your Family
In the Workplace
Motley Rice Ranked A Best Law Firm by U.S. News and World Report
Tampa Toddler Dies After Being Left In Vehicle
Burn Advocates Network Returns From Mission In Haiti
Update: Burn Advocates Network In Haiti
Burn Advocates Network In Haiti